| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1990.8.2.272 |
| P698 | PubMed publication ID | 2299370 |
| P50 | author | Michel Henry-Amar | Q45894648 |
| P2093 | author name string | B Desablens | |
| P Casassus | |||
| H Tilly | |||
| L Degos | |||
| S Castaigne | |||
| D Bordessoule | |||
| P Y Le Prisé | |||
| G Tertian | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cytarabine | Q180983 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 272-279 | |
| P577 | publication date | 1990-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly | |
| P478 | volume | 8 |
| Q36244164 | A Guide to Risk Assessment in the Primary Myelodysplastic Syndrome |
| Q79812026 | A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment |
| Q33392683 | A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia |
| Q35125889 | A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. |
| Q53618653 | A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. |
| Q36663603 | Acute myeloid leukaemia |
| Q40485001 | Acute myeloid leukaemia in the elderly: biology and treatment |
| Q34808062 | Acute myeloid leukaemia: optimising treatment in elderly patients |
| Q38234863 | Acute myeloid leukemia and myelodysplastic syndromes in older adults |
| Q38026008 | Acute myeloid leukemia in older adults |
| Q77326325 | Acute myeloid leukemia in the elderly |
| Q33684133 | Acute myeloid leukemia in the elderly: 'per aspera ad astra'? |
| Q37424101 | Acute myeloid leukemia in the elderly: biological features and search for adequate treatment |
| Q34334070 | Acute myeloid leukemia in the elderly: biology and therapeutic strategies. |
| Q38124066 | Acute myeloid leukemia in the elderly: do we know who should be treated and how? |
| Q26740584 | Acute myeloid leukemia in the older adults |
| Q73127004 | Adult acute leukemia |
| Q44915598 | Age and the biology of acute myeloid leukemia |
| Q84563146 | Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program |
| Q36849372 | Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group |
| Q36805563 | Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients |
| Q36850764 | Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better |
| Q38903073 | CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity |
| Q48305735 | Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach |
| Q37732543 | Chemotherapy of acute myelogenous leukaemia |
| Q27022725 | Clinical Results of Hypomethylating Agents in AML Treatment |
| Q37545335 | Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study |
| Q31801418 | De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy |
| Q45026144 | Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome |
| Q37568244 | Decitabine in the treatment of acute myeloid leukemia in elderly patients |
| Q41334613 | Differentiation, differentiation/gene therapy and cancer |
| Q77143170 | Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside |
| Q39389926 | Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve? |
| Q46168137 | Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults |
| Q50660518 | End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. |
| Q88775163 | Enzymatic synthesis of random sequences of RNA and RNA analogues by DNA polymerase theta mutants for the generation of aptamer libraries |
| Q33863567 | Epigenetic therapies in MDS and AML |
| Q72552402 | Factors associated with transfusion requirements during treatment for acute myelogenous leukemia |
| Q26825765 | Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy |
| Q33375568 | Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study |
| Q44048549 | Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia |
| Q34587614 | Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. |
| Q38212586 | Frontline therapy of AML: should the older patient be treated differently? |
| Q33341483 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome |
| Q38916984 | Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015. |
| Q33365723 | High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of age |
| Q37960820 | How to manage high-risk acute myeloid leukemia |
| Q80855046 | Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia |
| Q86809677 | Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia |
| Q40138696 | Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. |
| Q43461402 | Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? |
| Q70751298 | Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases |
| Q44133296 | Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy |
| Q37732531 | Low-dose chemotherapy and differentiating agents |
| Q73480344 | Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach |
| Q44589454 | Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission |
| Q38569175 | Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. |
| Q34893307 | Management of older or unfit patients with acute myeloid leukemia |
| Q54168804 | Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients |
| Q38651372 | Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly |
| Q34774180 | Older adults with acute myeloid leukemia |
| Q35579412 | Pharmacology of Anticancer Drugs in the Elderly Population |
| Q44663483 | Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study |
| Q35036913 | Primary vaginal myeloid sarcoma: a rare case report and review of the literature. |
| Q43758147 | Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases |
| Q43720980 | Prognosis of infections in elderly patients with haematological diseases |
| Q27024006 | Progress in acute myeloid leukemia |
| Q36498399 | Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia |
| Q82366072 | Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome |
| Q44271872 | Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives |
| Q37199950 | Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin |
| Q90590454 | Targeting apoptosis in cancer therapy |
| Q40485380 | The Approach to the Elderly Patient with Acute Myeloid Leukemia |
| Q54262552 | The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. |
| Q36746701 | The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome |
| Q80203294 | Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide |
| Q79722380 | Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions |
| Q34597777 | Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients |
| Q36662057 | Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine |
| Q35291847 | Treatment concepts for elderly patients with acute myeloid leukemia. |
| Q84912937 | Treatment of elderly acute myeloid leukemia patients |
| Q41476734 | Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience |
| Q92218684 | Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma |
Search more.